financetom
Business
financetom
/
Business
/
Vicor Insider Sold Shares Worth $8,870,435, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vicor Insider Sold Shares Worth $8,870,435, According to a Recent SEC Filing
Mar 12, 2026 12:41 PM

03:26 PM EDT, 03/12/2026 (MT Newswires) -- Patrizio Vinciarelli, 10% Owner, Director, Chairman and CEO, on March 11, 2026, sold 50,000 shares in Vicor ( VICR ) for $8,870,435. Following the Form 4 filing with the SEC, Vinciarelli has control over a total of 9,579,288 common shares of the company, with 9,408,163 shares held directly and 171,125 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/751978/000119312526103936/xslF345X05/ownership.xml

Price: 166.95, Change: -11.88, Percent Change: -6.64

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Fisker's Operating Subsidiary Files for Bankruptcy Protection After EV Maker's Operating Warning
Fisker's Operating Subsidiary Files for Bankruptcy Protection After EV Maker's Operating Warning
Jun 18, 2024
08:44 AM EDT, 06/18/2024 (MT Newswires) -- Fisker operating subsidiary, Fisker Group, filed for bankruptcy protection amid mounting liquidity issues and a challenging macroeconomic environment, the electric vehicle manufacturer said Tuesday. The company filed for Chapter 11 protection in the District of Delaware on Monday. The automaker said it is in advanced talks with stakeholders regarding debtor-in-possession financing and the...
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Jun 18, 2024
Tuesday, Zentalis Pharmaceuticals Inc ( ZNTL ) announced that the FDA has placed a partial clinical hold on the following studies of azenosertib: Phase 1 ZN-c3-001 dose-escalation study in solid tumors. Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC). Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC). This action follows two recent deaths due to presumed sepsis...
Cedar Fair, Six Flags Say Merger Set for July 1 Completion
Cedar Fair, Six Flags Say Merger Set for July 1 Completion
Jun 18, 2024
08:46 AM EDT, 06/18/2024 (MT Newswires) -- Cedar Fair ( FUN ) and Six Flags Entertainment ( SIX ) said Tuesday they expect their merger to be completed on July 1, pending regulatory approvals and other conditions. The entertainment facilities operating companies said the planned leadership team of the merged company includes Cedar Chief Executive Richard Zimmerman as president and...
Hedge Funds Betting On M&A Outperform Peers, But Lag Behind 2021 Levels
Hedge Funds Betting On M&A Outperform Peers, But Lag Behind 2021 Levels
Jun 18, 2024
In a recent report, Goldman Sachs revealed that hedge funds focusing on mergers and acquisitions have outperformed their peers in the first five months of 2024. What Happened: M&A-focused hedge funds have seen a 7.7% return in the first five months of 2024. This is a significant turnaround from the negative 0.8% return in the same period of 2023 when...
Copyright 2023-2026 - www.financetom.com All Rights Reserved